{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:52:03Z","timestamp":1781549523187,"version":"3.54.5"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1755","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved Yuvezzi (Tenpoint), an ophthalmic solution containing the cholinergic agonist carbachol 2.75% and the alpha-adrenergic receptor agonist brimonidine 0.1%, for treatment of presbyopia. Carbachol and brimonidine have been available in single-ingredient ophthalmic solutions for other indications for years.<\/jats:p>","DOI":"10.58347\/tml.2026.1755b","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:55:49Z","timestamp":1781546149000},"page":"84-85","source":"Crossref","is-referenced-by-count":0,"title":["Yuvezzi \u2014 A Carbachol\/Brimonidine Solution for Presbyopia"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,5,25]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:55:49Z","timestamp":1781546149000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1755b"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":0,"journal-issue":{"issue":"1755","published-online":{"date-parts":[[2026,5,25]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1755b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]}}}